Ionis Pharmaceuticals Inc
Research Ionis Pharmaceuticals Inc (IONS) on Bullrun: market cap USD 10.53B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIONS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.53B
- Financial periodQ2 2026
- RevenueUSD 267.95M
- Net income-USD 114.65M
- Free cash flowUSD 547.30M
- Gross margin99.0%
Valuation Snapshot
latest market cap is USD 10.53B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 943.71M | -USD 381.39M | -USD 320.03M | 98.3% | -2.38 | USD 372.26M | USD 1.76B | USD 489.09M |
| FY2024 | USD 705.14M | -USD 453.90M | -USD 546.23M | 98.4% | -3.04 | USD 242.08M | USD 1.20B | USD 588.35M |
| FY2023 | USD 787.65M | -USD 366.29M | -USD 331.32M | 98.8% | -2.56 | USD 399.27M | USD 1.24B | USD 386.69M |
| FY2022 | USD 587.37M | -USD 269.72M | -USD 290.09M | 97.6% | -1.9 | USD 276.47M | USD 1.18B | USD 572.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.53B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.92B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.52B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.26B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.37B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.30B | n/a | n/a | n/a |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ionis Pharmaceuticals Inc's market cap?
Ionis Pharmaceuticals Inc's market capitalization is USD 10.53B.
What does Ionis Pharmaceuticals Inc do?
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).